Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
1. A method of eliciting an immune response in a patient who has cancer overexpressing a PHTF1 or PHTF2 polypeptide comprising the amino acid sequence of SEQ ID NO: 18, comprising administering to the patient an effective number of activated T lymphocytes that kill cancer cells,
wherein the activated T cells are cytotoxic CD8+ T cells produced by contacting T cells with an antigen presenting cell that presents a peptide consisting of the amino acid sequence of SEQ ID NO: 18 in a complex with an MHC class I molecule on the surface of the antigen presenting cell in vitro, for a period of time sufficient to activate said T cell,
wherein the cancer is selected from the group consisting of non-small cell lung cancer, kidney cancer, stomach cancer, liver cancer, pancreatic cancer, prostate cancer, breast cancer, ovarian cancer, esophageal cancer, small cell lung cancer, melanoma, gallbladder cancer, and bile duct cancer.
2. The method of claim 1 , wherein the T cells are autologous to the patient.
3. The method of claim 1 , wherein the T cells are obtained from a healthy donor.
4. The method of claim 1 , wherein the T cells are obtained from tumor infiltrating lymphocytes or peripheral blood mononuclear cells.
5. The method of claim 1 , wherein the activated T cells are expanded in vitro.
6. The method of claim 5 wherein the expansion is in the presence of an anti-CD28 antibody and IL-12.
7. The method of claim 1 , wherein the antigen presenting cell is infected with a recombinant virus expressing the peptide.
8. The method of claim 7 , wherein the antigen presenting cell is a dendritic cell or a macrophage.
9. The method of claim 1 , further comprising administering to the patent an adjuvant selected from the group consisting of anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, Sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, and particulate formations with poly(lactide coglycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.
10. The method of claim 1 , wherein the MHC molecule is HLA-A*02.
11. The method of claim 1 , wherein the cancer is non-small cell lung cancer.
12. The method of claim 1 , wherein the cancer is kidney cancer.
13. The method of claim 1 , wherein the cancer is stomach cancer.
14. The method of claim 1 , wherein the cancer is liver cancer.
15. The method of claim 1 , wherein the cancer is pancreatic cancer.
16. The method of claim 1 , wherein the cancer is prostate cancer.
17. The method of claim 1 , wherein the cancer is breast cancer.
18. The method of claim 1 , wherein the cancer is ovarian cancer.
19. The method of claim 1 , wherein the cancer is esophageal cancer.
20. The method of claim 1 , wherein the cancer is small cell lung cancer.
21. The method of claim 1 , wherein the cancer is melanoma.
22. The method of claim 1 , wherein the cancer is gallbladder cancer.
23. The method of claim 1 , wherein the cancer is bile duct cancer.